From Surf Wiki (app.surf) — the open knowledge base
7,12-Dimethylbenz(a)anthracene
7,12-Dimethylbenzanthracene 7,12-Dimethyltetraphene 1,4-Dimethyl-2,3-benzophenanthrene | NFPA-H = 2 | NFPA-R = 0 | NFPA-F = 0 | NFPA-S =
7,12-Dimethylbenz[a]anthracene (DMBA) is an immunosuppressor and a powerful organ-specific laboratory carcinogen. DMBA is widely used in many research laboratories studying cancer. DMBA serves as a tumor initiator. Tumor promotion can be induced with treatments of 12-O-tetradecanoylphorbol-13-acetate (TPA) in some models of two-stage carcinogenesis. This allows for a greatly accelerated rate of tumor growth, making many cancer studies possible.
References
References
- [http://www.sigmaaldrich.com/catalog/search/ProductDetail/SIGMA/D3254 7,12-Dimethylbenz(a)anthracene] at [[Sigma-Aldrich]]
- Miyata M. (2001). "Mechanism of 7, 12-Dimethylbenz[a]anthracene-Induced Immunotoxicity: Role of Metabolic Activation at the Target Organ". Jpn J Pharmacol.
- Sung YM. (2005). "Lack of Expression of the EP2 but not EP3 Receptor for Prostaglandin E2 Results in Suppression of Skin Tumor Development". Cancer Res.
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about 7,12-Dimethylbenz(a)anthracene — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report